Blueprint raises $60M builds consumer clinical longevity platform

Blueprint, the longevity venture led by entrepreneur Bryan Johnson, has closed a new financing round that will accelerate its shift from a retail supplements line into a comprehensive, consumer-facing longevity service. The raise totals $60 million and brings a roster of high-profile individual backers, underscoring how anti-ageing science is moving into mainstream wellness.

Investors included high-profile backers such as Kim Kardashian, Naval Ravikant, Alex Hormozi, Ari Emanuel, and the Winklevoss twins

Johnson, best known for his public experiment with extreme health optimisation, announced the round on social media and positioned the capital as fuel to bundle clinical diagnostics with consumer products. Under the plan, Blueprint will broaden its current catalogue—already comprising olive oils and a marketed “longevity mix”—into a layered offering that combines blood testing, prescription access, nutrition, advanced therapies and an AI health companion.

The investor list is notable for its celebrity and founder mix: public figures and founders have taken stakes, signalling increasing cultural acceptance of longevity as a consumer category. That celebrity participation matters commercially; it helps brands win attention as the global anti-ageing and wellness markets remain competitive. Analysts estimate the broader anti-ageing market sits in the tens of billions of dollars with mid-single-digit to high-single-digit annual growth, while demand for personalised health services and at-home diagnostics is rising rapidly.

Operationally, Blueprint is hiring for a new phase. Johnson named Gyre Renwick as CEO — a leader with prior roles at Modern Health and stints in corporate healthcare teams — to guide the company through clinicalisation and scale. The move reflects a broader strategy: turn personalised protocols into deliverable products and services that meet regulatory and clinical standards, rather than remain purely aspirational supplements.

What Blueprint intends to sell is a hybrid: consumer convenience knit to clinical inputs. Customers could receive personalised supplement bundles, periodic biomarker panels, guidance on therapeutics such as GLP-1 agents where appropriate, and digital monitoring via an AI assistant. Turning that vision into a reproducible business will require investment in lab partnerships, telehealth infrastructure, prescriptions management and data systems — precisely where the new funding will be directed.